Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Front-End Governance of Juvenile Cybercrime in China: Platform Accountability, Risk Mitigation, and Tri-Partite Collaboration.

Behavioral sciences & the law·2026
Same author

Near-athermal silicon nitride 4-channel O-band (de)multiplexer with ~2 pm/K temperature sensitivity.

Optics letters·2026
Same author

The Potential Role of Camel Milk in Alleviating Chronic Fatigue Syndrome in Mice: A Network Pharmacology and In Vivo Validation Study.

Foods (Basel, Switzerland)·2026
Same author

Reconfigurable Organic Phototransistor Array by Scalable Photolithography for Near-Infrared Image Sensing and Recognition.

ACS applied materials & interfaces·2026
Same author

Source apportionment and health risk prioritization of groundwater contamination in a coal-mining area: An integrated SOM-PMF-Monte Carlo framework.

Journal of environmental management·2026
Same author

Non-HDL-to-HDL cholesterol ratio predicts incident T2DM and CHD in non-alcoholic fatty liver disease: evidence from a large clinical cohort and NHANES.

Frontiers in nutrition·2026

Related Experiment Videos

Albumin and Bleeding Risk in Hospitalized Patients Receiving Apixaban.

Ashley E Woodruff1,2, Shiqi Zhang1, Bidoura Chowdhury1

  • 1University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; and.

Journal of Cardiovascular Pharmacology
|July 14, 2026
PubMed
Summary

Low serum albumin levels in patients taking apixaban are linked to a higher risk of bleeding events. This finding suggests monitoring albumin is important for these patients to mitigate bleeding risks.

Keywords:
albuminapixabanbleedingdirect oral anticoagulantmonitoring

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Internal Medicine

Background:

  • Highly protein-bound anticoagulants like warfarin and rivaroxaban increase bleeding risk in hypoalbuminemia.
  • Apixaban, also highly protein-bound, has unevaluated bleeding risks in hypoalbuminemic patients.

Purpose of the Study:

  • To evaluate the association between serum albumin levels and bleeding events in hospitalized adults receiving apixaban.

Main Methods:

  • Retrospective cohort study of 391 hospitalized adults who received apixaban and had serum albumin measured.
  • Bleeding events assessed per International Society on Thrombosis and Hemostasis criteria.
  • Multivariable logistic regression analyzed the relationship between albumin, covariates, and bleeding.

Main Results:

  • A significant association was found between bleeding events and lower serum albumin levels (OR 2.10 per 1 g/dL reduction).
  • High-risk IMPROVE Bleeding scores (OR 2.17) and active gastroduodenal ulcer (OR 5.20) were also associated with bleeding.
  • 49 patients experienced bleeding events, while 342 did not.

Conclusions:

  • Serum albumin levels are relevant when assessing bleeding risk in patients treated with apixaban.
  • Consideration of albumin levels may help personalize anticoagulant therapy and reduce bleeding complications.